Standard newborn screening can detect dozens of inherited diseases, but genomics technology enables testing for hundreds of them. A North Carolina program evaluating the feasibility of bringing genomics to newborn screening is expanding with an initial goal of testing 5,000 babies in the next year.
The innovation institute run by the University of North Carolina at Chapel Hill teamed up with Amazon Web Services to create a venture studio to turn the university’s digital health research concepts into full-fledged startups. AWS’ platform beat out the other major cloud providers because it was “the most entrepreneurial,” according to the venture studio’s managing director.
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Chemotherapy drugs used today are potent and nonselective, meaning they kill both cancerous and non-cancerous cells. That’s why many cancer patients experience so many troublesome side effects. It’s also why a pair of University of North Carolina researchers want the healthcare industry to remember to ask another question: Are these drugs handled as safely as […]
Some newborns are testing positive for marijuana exposure and the reason why could surprise you. Soap and hand wash products, including products commonly used in hospital nurseries, can interfere with urine drug tests of newborns and lead to false positives, according to a new study from the University of North Carolina at Chapel Hill. The […]
The hepatitis C virus is believed to have links to the growth of liver cancer, but those connections have been hard to study. University of North Carolina at Chapel Hill research aimed at learning more about those connections has secured a $2.35 million federal grant. The five-year grant from the National Cancer Institute will enable […]
Don Rose has a front seat to watch many of the emerging life science companies around North Carolina’s Research Triangle Park. Rose is executive director of Carolina KickStart, a University of North Carolina at Chapel Hill program that helps faculty turn their university research and discoveries into new companies. Each year, Carolina KickStart hosts its […]
Innovation is brewing in Chapel Hill, North Carolina. The University of North Carolina at Chapel Hill held its annual Emerging Company Showcase this week, an event that gives companies spun out of the university the chance to strut their stuff in an eight minute presentation before an audience of researchers, entrepreneurs and potential investors or […]
In prostate cancer treatment, newer might not necessarily be better. University of North Carolina at Chapel Hill research has found that intensity modulated radiation therapy, or IMRT, is as effective and produces fewer side effects than the newer and more expensive proton therapy. And IMRT is better than conventional radiation therapy for reducing side effects […]
Kidney cancer research at the University of North Carolina at Chapel Hill is getting a funding boost from SAIC-Frederick with the goal of developing new treatments for renal cell carcinoma, the most common type of kidney cancer in adults. UNC’s Center for Integrative Chemical Biology and Drug Discovery (CICBDD) will receive $843,000 over 18 months […]
Angelman syndrome has no cure and few treatments but the rare genetic disorder now has the first clinic in the nation dedicated to the condition. The University of North Carolina at Chapel Hill has opened its Comprehensive Angelman Syndrome Clinic to offer counseling, support and services to patients who have Angelman syndrome. The clinic, a […]
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
